YD Bio enters MOU to merge with EG BioMed

YD Bio (YDES)announced that the Company has entered into a Memorandum of Understanding, MOU, to merge with EG BioMed. The MOU is non-binding and there can be no assurance that the parties will enter into definitive agreements, obtain required approvals, or consummate the merger on the terms contemplated or on any particular timeline. Any integration benefits, including potential revenue growth, platform expansion, or cost synergies, remain subject to numerous assumptions and risks and may not be realized1. The transaction is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.